Ovarian Cancer Drug Shows Promise

Wednesday, 12 Jun 2013 12:01 PM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink

Amgen Inc said on Wednesday that its trebananib treatment for ovarian cancer had reduced the risk of disease progression or death by 34 percent in a clinical trial.
 
The company said the drug had met its primary goal in the trial, which is the first of three for the new treatment.
 
Amgen said that while it was working on the primary analysis of overall survival for 2014, it saw a favorable survival trend in an interim analysis.
 
Shares in Amgen were up slightly $98.25 in Nasdaq morning trading.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Mom's Depression Linked to Delinquent Kids

Monday, 22 Dec 2014 08:23 AM

Teens are more likely to smoke, drink and use marijuana -- and to doso at an earlier age -- if their mothers were depres . . .

FDA OKs First New Flu Treatment in 15 Years

Monday, 22 Dec 2014 08:19 AM

The U.S. Food and Drug Administration approved Biocryst Pharmaceuticals' intravenous flu drug, sending the company's sha . . .

Activity Trackers Get Smarter

Monday, 22 Dec 2014 08:11 AM

Fitness activity trackers have come a long way since Leonardo da Vinci sketched a rudimentary gear-and-pendulum pedomete . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved